Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence.

external beam radiation therapy
luteinizing hormone
immunological adjuvant
adenocarcinoma
luteinizing hormone-releasing hormone agonist
  • 73 views
  • 20 Jul, 2022
  • 72 locations
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen

  • 0 views
  • 04 Aug, 2021
  • 1 location
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy

adenocarcinoma of prostate
androgens
adenocarcinoma
brachytherapy
androgen suppression
  • 85 views
  • 10 Nov, 2021
  • 5 locations
Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

central androgen suppression and brachytherapy.

brachytherapy
flutamide
androgen suppression
androgens
  • 0 views
  • 19 Sep, 2022
  • 1 location
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (the phase 1 portion of the study) and determine 3-year biochemical PSA recurrence free-survival with this treatment approach (the phase 2 portion of the …

androgen suppression
adenocarcinoma of prostate
prednisone
androgens
adenocarcinoma
  • 0 views
  • 15 Dec, 2021
  • 4 locations
Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer

treatment combination of the drugs abiraterone acetate and prednisone (AAP) given with androgen deprivation therapy (ADT, also known as androgen deprivation therapy or androgen suppression medication, which

  • 0 views
  • 19 Aug, 2022
  • 1 location
Optimizing Prostate Cancer Treatment in Men With Advanced Local Disease (OPTiMAL)

not compromising the unprecedented high cure rates obtained for the brachytherapy arm of the Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT

external beam radiation therapy
ct scan
brachytherapy
transrectal ultrasound
rectal ultrasound
  • 18 views
  • 12 Feb, 2022
  • 1 location
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

The purpose of this study is to compare urinary and bowel side effects of hypofractionated radiotherapy in 20 treatments (4 weeks) to ultra-hypofractionated radiotherapy in 5 treatments (2 weeks) for prostate cancer that has returned after prostatectomy. The investigators are also interested in looking at time to progression and the …

prostatectomy
bone scan
hypofractionated radiation therapy
metastasis
  • 0 views
  • 29 Jul, 2022
  • 1 location
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer (PROMPT)

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the …

immunological adjuvant
adenocarcinoma
testosterone
prostate specific antigen
gonadotropin
  • 3 views
  • 25 Feb, 2022
  • 2 locations
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer (MRFLA)

This serves as a registration trial. It aims to record short, intermediate, and long-term outcomes of patients treated with targeted laser ablation of biopsy confirmed prostate cancer. Outcomes will be categorized as: 1- Procedure Related, 2- Perioperative - Adverse Events that may occur within 90 days, 3-Oncologic: Recurrence of cancer …

  • 0 views
  • 25 Mar, 2022
  • 1 location